摘要
目的:探讨强肝丸联合抗病毒治疗对代偿期乙肝肝硬化患者纤维化指标、免疫及炎症反应的影响。方法:收集2013年4月~2016年3月间本院收治的代偿期乙肝肝硬化患者88例,根据单盲随机对照法分为观察组、对照组,观察组患者接受强肝丸联合抗病毒治疗,对照组患者仅接受抗病毒治疗。治疗后6个月时,采用化学发光法检测血清纤维化指标,采用流式细胞仪检测外周血T淋巴细胞亚群水平,采用酶联免疫吸附法(ELISA)检测血清炎症因子含量。结果:治疗前,两组纤维化指标、免疫及炎症反应指标的差异无统计学意义(P>0.05);治疗6个月后,观察组血清层黏连蛋白(LN)、透明质酸(HA)、Ⅳ型胶原(Ⅳ-C)含量低于对照组,外周血CD3^+、CD4^+T淋巴细胞水平,CD4^+/CD8^+比值高于对照组,CD8^+T淋巴细胞水平低于对照组;血清降钙素原(PCT)、C反应蛋白(CRP)含量低于对照组,白介素(IL)-10、IL-13含量高于对照组(P<0.05)。结论:强肝丸联合抗病毒治疗可抑制代偿期乙肝肝硬化患者纤维化进程,在增强机体免疫功能的同时缓解全身炎症反应。
Objective:To study the effect of Qianggan Pills combined with antiviral treatment on the fibrosis indexes,immune and inflammatory response in patients with compensated hepatitis b cirrhosis.Methods:A total of 88 patients with compensated hepatitis b cirrhosis treated in our hospital between April 2013 and March 2016 were collected and divided into observation group and control group according to single blind randomized control.Observation group of patients accepted Qianggan Pills combined with antiviral treatment and control group of patients received antiviral treatment alone.After 6months of treatment,chemiluminescence method was used to detect serum fibrosis indexes,flow cytometer was used to detect peripheral blood T lymphocyte subset levels,and enzyme-linked immunosorbent assay(ELISA)was used to detect serum levels of inflammatory factors.Results:Before treatment,differences in fibrosis indexes,immune and inflammatory response indexes were not statistically significant between two groups of patients(P〉0.05);after 6months of treatment,serum LN,HA andⅣ-C levels of observation group were lower than those of control group,peripheral blood CD3+and CD4+T lymphocyte levels as well as CD4+/CD8+ratio were higher than those of control group,and CD8+T lymphocyte level was lower than that ofcontrol group;serum PCT and CRP levels were lower than those of control group while IL-10 and IL-13 levels were higher than those of control group(P〈0.05).Conclusions:Qianggan Pills combined with antiviral treatment can inhibit the fibrosis process,strengthen the body's immune function and also relieve systemic inflammatory response in patients with compensated hepatitis b cirrhosis.
作者
黄红刚
HUANG Hong-gang(Department of Liver Diseases, Xinzhou District Hospital of TCM , Wuhan City 430000, Hubei Province, Chin)
出处
《海南医学院学报》
CAS
2017年第4期489-492,共4页
Journal of Hainan Medical University
基金
武汉市卫生局一般项目(1403635)~~
关键词
代偿期乙肝肝硬化
强肝丸
纤维化
免疫功能
炎症反应
Compensated hepatitis b cirrhosis
Qianggan Pills fibrosis
Immune function
Inflammatory response